度普利尤单抗治疗的两名患有大疱性类天疱疮伴角化过度和掌跖角化病患者的临床改善情况 - Suppr

Suppr

超能文献

Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab.

作者信息

Pascolini Giulia, Mariotti Feliciana, Pira Anna, Didona Biagio, Di Zenzo Giovanni

机构信息

Rare Skin Diseases Center, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.

出版信息

Acta Derm Venereol. 2024 Oct 10;104:adv41984. doi: 10.2340/actadv.v104.41984.

DOI:10.2340/actadv.v104.41984

PMID:39387672

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11481302/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/11481302/0267ae59b6a0/ActaDV-104-41984-g001.jpg

相似文献

Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab.

Acta Derm Venereol. 2024 Oct 10;104:adv41984. doi: 10.2340/actadv.v104.41984.

Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.

J Dermatol. 2018 Sep;45(9):1135-1140. doi: 10.1111/1346-8138.14529. Epub 2018 Jul 14.

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

Front Immunol. 2021 Jan 29;11:611549. doi: 10.3389/fimmu.2020.611549. eCollection 2020.

[Initial manifestation of bullous pemphigoid simulating dyshidrosis palmoplantaris].

Hautarzt. 1994 Feb;45(2):97-9. doi: 10.1007/pl00013265.

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

J Am Acad Dermatol. 2020 Jul;83(1):46-52. doi: 10.1016/j.jaad.2020.01.089. Epub 2020 Mar 13.

Palmoplantar psoriasis or palmoplantar keratoderma? Successful treatment with brodalumab.

Int J Dermatol. 2024 Sep;63(9):1272-1273. doi: 10.1111/ijd.17159. Epub 2024 Apr 10.

Successful treatment of bullous pemphigoid with omalizumab.

Arch Dermatol. 2012 Nov;148(11):1241-3. doi: 10.1001/archdermatol.2012.1604.

Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.

Australas J Dermatol. 2021 Nov;62(4):525-527. doi: 10.1111/ajd.13692. Epub 2021 Aug 26.

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Front Immunol. 2021 Oct 14;12:738907. doi: 10.3389/fimmu.2021.738907. eCollection 2021.

Successful management of severe infant bullous pemphigoid with omalizumab.

Br J Dermatol. 2012 May;166(5):1140-2. doi: 10.1111/j.1365-2133.2011.10748.x. Epub 2012 Mar 2.

本文引用的文献

Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.

J Drugs Dermatol. 2024 Jun 1;23(6):e144-e148. doi: 10.36849/JDD.8258.

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.

Int Immunopharmacol. 2023 Dec;125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157. Epub 2023 Nov 3.

Evaluation of Dupilumab in Patients With Bullous Pemphigoid.

JAMA Dermatol. 2023 Sep 1;159(9):953-960. doi: 10.1001/jamadermatol.2023.2428.

Dupilumab in the treatment of genodermatosis: A systematic review.

J Dtsch Dermatol Ges. 2023 Jan;21(1):7-17. doi: 10.1111/ddg.14924. Epub 2023 Jan 19.

Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.

Front Immunol. 2022 Dec 8;13:1054422. doi: 10.3389/fimmu.2022.1054422. eCollection 2022.

Treatment of Netherton syndrome with dupilumab.

J Dtsch Dermatol Ges. 2022 Dec;20(12):1636-1640. doi: 10.1111/ddg.14914. Epub 2022 Nov 2.

A Netherton syndrome case report: Response to dupilumab treatment.

Dermatol Ther. 2022 Nov;35(11):e15862. doi: 10.1111/dth.15862. Epub 2022 Oct 6.

Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome.

Australas J Dermatol. 2022 Nov;63(4):527-529. doi: 10.1111/ajd.13913. Epub 2022 Sep 6.

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Front Immunol. 2022 Jun 13;13:928621. doi: 10.3389/fimmu.2022.928621. eCollection 2022.

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1689-1704. doi: 10.1111/jdv.18220. Epub 2022 Jun 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab.

Acta Derm Venereol. 2024 Oct 10;104:adv41984. doi: 10.2340/actadv.v104.41984.

Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.

J Dermatol. 2018 Sep;45(9):1135-1140. doi: 10.1111/1346-8138.14529. Epub 2018 Jul 14.

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

Front Immunol. 2021 Jan 29;11:611549. doi: 10.3389/fimmu.2020.611549. eCollection 2020.

[Initial manifestation of bullous pemphigoid simulating dyshidrosis palmoplantaris].

Hautarzt. 1994 Feb;45(2):97-9. doi: 10.1007/pl00013265.

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

J Am Acad Dermatol. 2020 Jul;83(1):46-52. doi: 10.1016/j.jaad.2020.01.089. Epub 2020 Mar 13.

Palmoplantar psoriasis or palmoplantar keratoderma? Successful treatment with brodalumab.

Int J Dermatol. 2024 Sep;63(9):1272-1273. doi: 10.1111/ijd.17159. Epub 2024 Apr 10.

Successful treatment of bullous pemphigoid with omalizumab.

Arch Dermatol. 2012 Nov;148(11):1241-3. doi: 10.1001/archdermatol.2012.1604.

Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.

Australas J Dermatol. 2021 Nov;62(4):525-527. doi: 10.1111/ajd.13692. Epub 2021 Aug 26.

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Front Immunol. 2021 Oct 14;12:738907. doi: 10.3389/fimmu.2021.738907. eCollection 2021.

Successful management of severe infant bullous pemphigoid with omalizumab.

Br J Dermatol. 2012 May;166(5):1140-2. doi: 10.1111/j.1365-2133.2011.10748.x. Epub 2012 Mar 2.

本文引用的文献

Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.

J Drugs Dermatol. 2024 Jun 1;23(6):e144-e148. doi: 10.36849/JDD.8258.

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.

Int Immunopharmacol. 2023 Dec;125(Pt A):111157. doi: 10.1016/j.intimp.2023.111157. Epub 2023 Nov 3.

Evaluation of Dupilumab in Patients With Bullous Pemphigoid.

JAMA Dermatol. 2023 Sep 1;159(9):953-960. doi: 10.1001/jamadermatol.2023.2428.

Dupilumab in the treatment of genodermatosis: A systematic review.

J Dtsch Dermatol Ges. 2023 Jan;21(1):7-17. doi: 10.1111/ddg.14924. Epub 2023 Jan 19.

Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.

Front Immunol. 2022 Dec 8;13:1054422. doi: 10.3389/fimmu.2022.1054422. eCollection 2022.

Treatment of Netherton syndrome with dupilumab.

J Dtsch Dermatol Ges. 2022 Dec;20(12):1636-1640. doi: 10.1111/ddg.14914. Epub 2022 Nov 2.

A Netherton syndrome case report: Response to dupilumab treatment.

Dermatol Ther. 2022 Nov;35(11):e15862. doi: 10.1111/dth.15862. Epub 2022 Oct 6.

Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome.

Australas J Dermatol. 2022 Nov;63(4):527-529. doi: 10.1111/ajd.13913. Epub 2022 Sep 6.

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Front Immunol. 2022 Jun 13;13:928621. doi: 10.3389/fimmu.2022.928621. eCollection 2022.

Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1689-1704. doi: 10.1111/jdv.18220. Epub 2022 Jun 29.